scholarly journals Antiphospholipid Antibody Titers and Clinical Outcomes in Patients with Recurrent Miscarriage and Antiphospholipid Antibody Syndrome

2017 ◽  
Vol 130 (3) ◽  
pp. 267-272 ◽  
Author(s):  
Yu Song ◽  
Hai-Yan Wang ◽  
Jie Qiao ◽  
Ping Liu ◽  
Hong-Bin Chi
Keyword(s):  
Clinical Outcomes ◽  
Recurrent Miscarriage ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Antibody Titers

scholarly journals CRITICAL ANALYSIS OF JATAHARINIES WSR TO ANTIPHOSPHOLIPID ANTIBODY SYNDROME

2020 ◽  
pp. 95-102
Author(s):  
Sushma
Keyword(s):  
Critical Analysis ◽  
Recurrent Miscarriage ◽  
Intrauterine Fetal Death ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Intrauterine Death ◽  
Still Birth ◽  
Neonatal Deaths ◽  
History Of ◽  
Ayurvedic Treatment

Acharya Kashyapa in Revatikalpa adhyaya explained about the Jataharinies, as a group of demons who has divine vision, attack women to destroy or to produce serious problems of menstrual cycle, recurrent abortions, still birth, intrauterine fetal death, neonatal deaths or severe disorders which decreases the life span of the fetus. As recurrent miscarriage, intrauterine death of an infant or death at birth has always been a devastating experience for the mother and of concern in clinical practice. All these mortality remains a challenge in the care of pregnant women worldwide, particularly for those who had history of adverse outcome in previous pregnancies (BOH). Antiphospholipid antibody syndrome (Hughes syndrome) is an autoimmune, hypercoagulable state caused by antiphospholipid antibodies. Pregnancy related complications are miscarriage, still birth, preterm delivery, IUD etc. This is one of the few treatable causes of pregnancy loss, and successful pregnancy rates of 70% or more can be achieved with appropriate treatment. Description of Jataharinies resemble with APLA, hence critical analysis will help to emphasize on management of Jataharinies by Ayurvedic treatment principles.

Platelet-derived microparticles from recurrent miscarriage associated with antiphospholipid antibody syndrome influence behaviours of trophoblast and endothelial cells

2019 ◽  
Vol 25 (8) ◽  
pp. 483-494 ◽  
Author(s):  
Qian Zhou ◽  
Yan Lian ◽  
Yan Zhang ◽  
Lei Li ◽  
Hongyan Li ◽  
...  
Keyword(s):  
Cell Adhesion ◽  
Adhesion Molecule ◽  
Cell Adhesion Molecule ◽  
Recurrent Miscarriage ◽  
Umbilical Vein ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Invasion And Migration ◽  
Cell Adhesion Molecule 1

AbstractPlatelet-derived microparticles (PMPs) are a type of microparticle budding from platelets undergoing activation or apoptosis in many autoimmune diseases, including antiphospholipid antibody syndrome (APS). PMPs may also contribute to recurrent miscarriage, although the exact mechanism is unclear. The aim of this study was to determine the potential biological mechanism by which abnormal PMP activation may affect recurrent miscarriage. PMPs were counted by fluorescence-activated cell sorting (FACS) and compared between the healthy control (HC) and recurrent miscarriage/APS groups. Different effects of PMPs isolated by FACS from patients with recurrent miscarriage/APS and HCs were explored. Capillary electrophoresis immunoquantification, RT-qPCR, Luminex xMAP and immunofluorescence staining were performed to investigate all these different effects of PMPs. We found that the difference in the counts of PMP was not significant. However the expression of the inflammatory cytokine tumour necrosis factor-α (TNF-α) and the adhesion molecules intracellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) were increased by PMPs derived from the recurrent miscarriage/APS group. PMPs isolated from patients with recurrent miscarriage/APS also more potently stimulated monocyte recruitment, inhibited angiogenesis and promoted human umbilical vein endothelial cell (HUVEC) apoptosis, in comparison to PMPs from HCs matched for gestational week. Moreover, PMPs could be ternalized by HTR-8/SVneo cells and could increase apoptosis of these cells and decrease trophoblastic invasion and migration. To supplement our work, the limited sample size needs to be increased, and further in-vivo work is necessary. Findings from this study indicate that abnormal activation of PMPs contributes to recurrent miscarriage/APS progression and provides potential therapeutic targets.

scholarly journals The Screening of Antiphospholipid Antibodies in Obstetric Antiphospholipid Syndrome-Like Events: A Regional Perspective

2019 ◽  
pp. 1
Author(s):  
Onder Onen ◽  
Fusun Gulizar Varol
Keyword(s):  
Antiphospholipid Antibodies ◽  
Obstetric Outcomes ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Serum Samples ◽  
Laboratory Findings ◽  
Mean Values ◽  
Antibody Positivity ◽  
History Of ◽  
Antibody Titers

<p><strong>Objective</strong>: Obstetric antiphospholipid antibody syndrome is clinically recognized by adverse obstetric outcomes. To determine which antibody level best corresponds to the risk of these clinical outcomes is difficult. Obstetric antiphospholipid antibody syndrome-like adverse obstetric outcomes with single (n=108) and repeat (n=79) documented antiphospholipid antibody titers were evaluated.</p><p><strong>Study Design:</strong> Serum samples of 108 Obstetric antiphospholipid antibody syndrome cases and 50 healthy gestational matched controls with no history of thrombosis and congenital anomalies were subjected to testing for antiphospholipid antibodies with ELISA after the events. Of this obstetric antiphospholipid antibody syndrome group, only 79 cases underwent repeat testing within 12 weeks. Quantitative data were described by values and percentages at the levels of (&gt;10) and (&gt;40 U).</p><p><strong>Results:</strong> By one documented antiphospholipid test, the mean values of anticardiolipin, and anti-β2 glycoprotein1 (aβ2GP1) of obstetric antiphospholipid antibody syndrome versus controls were significantly different (p&lt;0.001). Of 79 women who came for repeat sampling, a total number of women with persistent antiphospholipid antibody positivity was only 43 (54.43%). The number of obstetric antiphospholipid antibody syndrome cases with &gt;40 U of antiphospholipid antibody was only 8 (18.60%). </p><p><strong>Conclusion:</strong> Not all obstetric antiphospholipid antibody syndrome associated pregnancy morbidities may own high (&gt;40U) antiphospholipid antibody titers, but low antiphospholipid antibodies (&gt;10U) also accompany to this clinical picture. Obstetric antiphospholipid antibody syndrome should always be taken into account clinically prior to laboratory findings. Besides, long persistence of antiphospholipid-M positivity in these placenta-mediated disorders may make sense in terms of trophoblastic damage.<br /><br /></p>

Procoagulant Microparticles: New Insights and Opportunities in Pregnancy Loss?

2001 ◽  
Vol 85 (01) ◽  
pp. 3-4 ◽  
Author(s):  
Ian Greer
Keyword(s):  
Pregnancy Complications ◽  
Pregnancy Loss ◽  
Recurrent Miscarriage ◽  
Fetal Loss ◽  
Medical Intervention ◽  
Coagulation System ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Intrauterine Death ◽  
Increased Risk

SummaryIn recent years, prothrombotic states have been not only associated with an increased risk of venous thrombosis, but also with pregnancy complications. In particular there is good evidence linking antiphospholipid antibody syndrome, which is associated with increased thrombin generation (1), to recurrent miscarriage. The importance of procoagulant changes in the pathophysiology of recurrent miscarriage is emphasised by the fact that treatment with heparin and low dose aspirin will substantially improve the likelihood of a successful pregnancy (2). Essentially, this is the only successful medical intervention in the treatment of miscarriage. There are also data now accumulating that link congenital thrombophilia to pregnancy complications such as miscarriage, pre-eclampsia, intra-uterine growth restriction, abruption and intrauterine death (3, 4). Furthermore, recent data have shown that acquired changes in the coagulation system, such as the acquired activated protein C resistance of pregnancy is also associated with an increased risk of pre-eclampsia (5). These data collectively suggest that procoagulant changes in general, rather than congenital or acquired thrombophilia in particular are associated with the development of pregnancy complications including fetal loss. However, in the majority of cases of fetal loss no cause is found and we cannot easily link these events to a procoagulant problem in the mother. In this issue of the Thrombosis and Haemostasis, Laude et al. (6) report, for the first time, the association between circulating procoagulant microparticles and pregnancy loss so providing a new insight into potential mechanisms.

scholarly journals Cluster-Based Immunotherapy for Patients with Recurrent Abortion Caused by Antiphospholipid Syndrome

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Ruifang Wang ◽  
Juanjuan Yu ◽  
Zhen Yan ◽  
Xiaolin Cheng ◽  
Jian Chen ◽  
...  
Keyword(s):  
Antiphospholipid Syndrome ◽  
Clustering Algorithm ◽  
Clinical Symptoms ◽  
Recurrent Miscarriage ◽  
Control Group ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Ultrasound Images ◽  
Observation Group ◽  
Hormone Levels

In order to diagnose patients with pregnancy and antiphospholipid antibody syndrome, provide early treatment, and effectively reduce the pregnancy outcome of the abnormal pregnancy, the effect of antiphospholipid syndrome (APS) immunotherapy on the incidence of abortion was discussed based on clustering algorithm. We selected 62 cases of APS leading to recurrent miscarriage patients, in the early pregnancy injection of low molecular heparin, intravenous drip proprocyclin, and oral tactics, using B-ultrasound images to observe the pregnancy ending. The results show that the hormone levels in the two groups were different before treatment ( P > 0.05 ); after treatment, the HCG, E2, and P hormone levels in the two groups were significantly improved, and the HCG, E2, and P hormone levels in the observation group were significantly higher than those of the control group ( P < 0.05 ); the abortion rate of patients in the observation group was significantly lower than that of the control group ( P < 0.05 ); the antiphosphorus antibody of the study group was significantly higher than that of the control group. For APS patients, immunotherapy is effective. Antiphospholipid syndrome causes remarkable immunotherapy effect in patients with recurrent miscarriage, effectively improves the clinical symptoms of patients, improves antiprochemical antibody rosion, and improves the patient’s pregnancy outcomes, which is worth promoting.

scholarly journals The study of antiphospholipid antibodies in recurrent pregnancy loss

2017 ◽  
Vol 6 (11) ◽  
pp. 5135
Author(s):  
Sheela H. S. ◽  
Lakshmidevi M. ◽  
Babitha Koganti ◽  
Shreedhar Venkatesh
Keyword(s):  
Pregnancy Loss ◽  
Recurrent Pregnancy Loss ◽  
Recurrent Miscarriage ◽  
Research Centre ◽  
Antiphospholipid Antibody ◽  
Significant Difference ◽  
Gynaecological Examination ◽  
History Of ◽  
Antibody Titers ◽  
The Difference

Background: Around 15% of clinically recognised pregnancies in women less than 35 years old result in spontaneous miscarriage. However recurrent pregnancy loss (RPL) is encountered in 5% of couples with two or more losses and in around 1–2% of couples with three or more losses. In view of the increasing burden of recurrent pregnancy loss in the society and in view of Anti-phospholipid syndrome being one of the undisputed treatable cause for recurrent pregnancy loss, this study aims to evaluate the significance of the antibody profiles of APS in relation to RPL in OBG dept of VIMS and RC.Methods: Patients coming to the Obstetric and Gynaecology department of Vydehi Institute of Medical Sciences and Research Centre, Bangalore, from December 1st 2014 to June 30th 2016. A detailed history of patients was taken based on set questionnaires. Detailed general and gynaecological examination findings were taken. Routine blood investigations were sent along with investigations for aPLAs which included: - Lupus Anticoagulant (LA) - Anti Cardiolipin Antibody (ACA) - Anti β2 glycoprotein 1 (Anti-β2GP1Ab). Final results are statistically evaluated.Results: A total of 56 patients of recurrent miscarriage with two or more prior pregnancy losses were considered. Out of the 56 patients, 23 patients were excluded as per the exclusion criteria and 33 patients were included in the present study. The mean age of the study group was 24.63 years (Range: 20-32 years). Overall, seven patients (21.21%) were seen to have positive antiphospholipid antibody titers amongst the 33 patients, with repeat testing done after 12 weeks to confirm the positivity. Five patients (15.15%) were positive for ACA antibody. Four (12.12%) patients were positive for LA and B2GP1 each. Two patients (6.06%) were positive for both LA and ACA antibodies. Two patients (6.06%) were positive for LA and B2GP1 antibodies and two other (6.06%) patients were positive for ACA and Anti-β2GP1Ab. There was a statistically significant association noticed between ACA positivity and POG at 1st pregnancy loss. However, the overall association of APLA positivity and POG at pregnancy loss was not statistically significant.Conclusions: There was a significant difference of POG at first pregnancy loss in ACA positive patients as compared to the ACA negative patients. However, when all the APLA positive patients were considered the difference was not statistically significant.

Plasma Levels of Lipoprotein(a) Are Elevated in Patients with the Antiphospholipid Antibody Syndrome

1994 ◽  
Vol 71 (04) ◽  
pp. 424-427 ◽  
Author(s):  
Masahide Yamazaki ◽  
Hidesaku Asakura ◽  
Hiroshi Jokaji ◽  
Masanori Saito ◽  
Chika Uotani ◽  
...  
Keyword(s):  
Plasma Levels ◽  
Active Form ◽  
Plasminogen Activator Inhibitor ◽  
Arterial System ◽  
Control Group ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Lipoprotein A ◽  
Soluble Thrombomodulin ◽  
Relationship Of

SummaryThe mechanisms underlying clinical abnormalities associated with the antiphospholipid antibody syndrome (APAS) have not been elucidated. We measured plasma levels of lipoprotein(a) [Lp(a)], the active form of plasminogen activator inhibitor (active PAI), thrombin-antithrombin III complex (TAT) and soluble thrombomodulin (TM), to investigate the relationship of these factors to thrombotic events in APAS. Mean plasma levels of Lp(a), TAT, active PAI and TM were all significantly higher in patients with aPL than in a control group of subjects. Plasma levels of Lp(a) and active PAI were significantly higher in patients with aPL and arterial thromboses than in patients with aPL but only venous thromboses. There was a significant correlation between plasma levels of Lp(a) and active PAI in patients with aPL. These findings suggest that patients with aPL are in hypercoagulable state. High levels of Lp(a) in plasma may impair the fibrinolytic system resulting in thromboses, especially in the arterial system.

Sign in / Sign up

Export Citation Format

Share Document